Mani, Inc.TSE: 7730

Script for Briefing on Financial Results for the First Quarter of the Fiscal Year Ending August 2025 and Medium-term Management Plan

· Issued by Mani, Inc.

MANI, INC.

Briefing on Financial Results for the First Quarter of the Fiscal Year Ending August 2025 and Medium-term Management Plan

January 9, 2025

Event Summary

[Company Name]

MANI, INC.

[Company ID]

7730-QCODE

[Event Language]

JPN

[Event Type]

Earnings Announcement

[Event Name]

Briefing on Financial Results for the First Quarter of the Fiscal Year Ending

August 2025 and Medium-term Management Plan

[Fiscal Period]

FY2025 Q1

[Date]

January 9, 2025

[Number of Pages]

42

[Time]

10:00 - 11:03

(Total: 63 minutes, Presentation: 37 minutes, Q&A: 26 minutes)

[Venue]

Onsite venue: Sapia Tower, 1-7-12 Marunouchi, Chiyoda-ku, Tokyo, 100-

0005

Webcast: Microsoft Teams webinar

[Venue Size]

231 m2

[Participants]

Total 134 (Onsite: 50, webinar 84)

[Number of Speakers]

2

Masaya Watanabe

Director, President and Representative

Executive Officer, CEO

Kazuo Takahashi

Director, Executive Vice President, Assistant

to the President (Special Appointive Officer),

CRO

[Analyst Names]*

Shinnosuke Tokumoto

SMBC Nikko Securities

Masao Yoshida

Tokai Tokyo Intelligence Laboratory

Satoshi Touyama

Shimotsuke Shimbun

*Analysts that SCRIPTS Asia was able to identify from the audio who spoke during Q&A or whose questions were read by moderator/company representatives.

Support

Japan

050.5212.7790

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

1

Presentation

Moderator: We will be holding a financial results presentation of MANI, INC. This information session will be held in a hybrid format, with a live-streaming online session in addition to the on-site session.

First of all, I would like to introduce two individuals from the Company. Mr. Masaya Watanabe, President and Representative Executive Officer. Mr. Kazuo Takahashi, Executive Vice President.

Mr. Takahashi, Vice President, will give an overview of the financial results, followed by Mr. Watanabe, President, who will explain the progress of the medium-term management plan and future management policies. After the explanation, there will be time for questions and answers for the audience. Please note that we will not be accepting questions from those participating online at this time. If you have any questions, please send an e-mail to the contact person for IR after today's presentation.

Now, let us start the presentation.

Takahashi: Good morning, everyone. Thank you for taking the time off your busy schedules to attend today's presentation. I would like to begin explaining our financial results for the first quarter of fiscal year 2025, and later, President Watanabe will explain the policies for the future.

First is the consolidated financial results summary, which is already disclosed.

Net sales grew by 7.6% on a year-on-year basis, while operating income decreased by 5.2% and ordinary income was down 2.2%.

Allow me to explain the details.

Support

Japan

050.5212.7790

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

2

This is the net sales status by segment. The waterfall chart shows the year-on-year change.

The foreign exchange rates for the various currencies we transact in remained fairly stable on a year-on-year basis, meaning that the impact was small compared to the previous period.

In the Surgical segment, as expected, we continued seeing growth in sales of ophthalmic knives, especially in China.

In the Eyeless needle segment, we also continued seeing sales growth, mainly in China.

Conversely, net sales were down 300 million yen in the Dental segment, and we have received a number of shareholder inquiries regarding this.

Results for our German subsidiary weren't stellar, but it nevertheless managed to grow sales by about 80 million yen. Conversely, sales decreased by 381 million yen at MANI Dental, which is our main entity selling our dental products. The primary cause for this decline is the Chinese market. More specifically, sales in China were down approximately 470 million yen on a year-on-year basis, and there are three factors causing this decline.

The first factor is the stagnant Chinese economy, and this has greatly affected the dental industry and, as we have explained in the past, that cosmetic dentistry products have been greatly affected, but we have come to recognize that it is also affecting our products.

The second factor is the voluntary recall of dia-burs, which negatively impacted results, and lastly, the third factor was changes in procedures in dental root canal treatment.

The second factor is the voluntary recall of dia-burs. We have recalled 2 lots, which negatively impacted results.

The third factor was changes in procedures in dental root canal treatment. We have received inquiries from stakeholders pertaining to these changes in procedures, as it is not clear to them what this involves.

Support

Japan

050.5212.7790

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

3

Usually, during dental root canal treatment, dentists insert a dental file into the dental cavity. The dental files MANI sells in China belong to a category of products known as "classic files," which are now old products. These files are inserted into the dental cavity and then rotated manually in the course of treatment.

The rotary file made of nickel-titanium is now becoming a mainstay in China. This file is attached to a hand motor and is rotated by the motor rather than by the dentists' hand. This file will grow significantly in the future since it will benefit dentists in many ways. MANI now offers "JIZAI," a new rotary file made of nickel- titanium.

Historically, MANI has captured significant market share in terms of classic dental files, but the overall market itself is undergoing a shift from hand files toward nickel-titanium rotary files with built-in motors.

These three factors therefore negatively impacted our results in China.

Next is the net sales status overview by region. The results here are in line with what I just said: while China had driven results in Asia up until now, the trend worked against us in the first quarter.

Support

Japan

050.5212.7790

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

4

Next is the operating income status. This waterfall chart shows the operating income status

Here, too, the impact from foreign exchange was less pronounced in the period under review.

Regarding the gross profit impact, an increase in sales positively impacted operating income, as did a rather significant improvement in the cost of sales ratio.

On the other hand, SG&A expenses had a negative impact of around 660 million yen. Particularly significant within this were bonuses linked to the Company's performance results in fiscal year 2024, as MANI pays both bonuses and performance units. These two items totaling 350 million yen weighed down on operating income.

Part of this amount was in line with the forecast, while another part was not, with approximately 200 million yen exceeding our forecast. The rest of the expenses, such as sales marketing costs and personnel costs, were in line with the budget and increased by approximately 312 million yen on a year-on-year basis.

All in all, in the first quarter, operating income decreased to 2.107 billion yen compared to 2.223 billion yen in the same period last year. However, this includes factors that occur only in the first quarter of fiscal year 2025, such as performance-linked bonuses of less than 200 million yen out of 350 million yen. Since expenses that should have been recorded in fiscal year 2024 are included, we believe that the actual value of operating income is approximately 2.4 billion yen.

Support

Japan

050.5212.7790

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

5

Next are the financial results by segment.

Overall, the Surgical and Eyeless Needle segments grew in line with expectations while the Dental segment came in slightly below target.

In terms of the business overview, we are seeing an increase in demand in the Surgical segment, primarily centered around MANI's ophthalmic knives.

Support

Japan

050.5212.7790

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

6

President Watanabe will be going over the specifics during his presentation, but, briefly, we expect this trend to continue into the future as we will be executing initiatives to further grow sales in the United States and Europe.

The Eyeless Needle segment, too, continues posting strong results, as MANI's needle superiority remains strong.

Support

Japan

050.5212.7790

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

7

Last is the Dental segment. Going back to what I mentioned earlier, this segment was negatively impacted by the Chinese market. Sales in China alone were down around 470 million yen from the same period of the previous fiscal year, which is about 200 million yen lower than our estimate.

As an ongoing factor, the overall dental market conditions and changes in root canal treatment will have an impact on the base.

The rollout of "JIZAI" is to rapidly make up for these changes in procedures. However, the product has not yet been approved in China, so quickly making progress on this front is a vital challenge we are working to overcome. "JIZAI" will have an impact not just in the Chinese market, but also globally.

Additionally, our composite resin retains its superior advantage over our competitors' products, so we will be making further efforts to expand this product.

Liabilities and net assets remain more or less unchanged.

This concludes my presentation. In summary, results were significantly impacted by factors specific to the first quarter, although it should be noted that we consider results to be more or less in line with Company forecasts.

A number of challenges remain, and addressing these is of vital importance for us as MANI's executive team.

I would now like to yield the floor to President Watanabe, who will be going over the Company's future management policies.

Support

Japan

050.5212.7790

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

8

Watanabe: My name is Masaya Watanabe, and I have been serving as President since last November. Allow me to use this opportunity to give you a status update on progress of the medium-term management plan and future management policies. Some topics played a role in the results for the first quarter, so we will be exploring these as well.

First of all, we have received the opinions from stakeholders who attended the Annual General Meeting of Shareholders and from others that we should manage the Company by inheriting the good qualities that made MANI great over the years. I concur with these opinions and would therefore like to enact management policies along those lines going forward.

In other words, MANI's corporate identity remains the same, as we are committed to continuing our vision of delivering "The Best Quality in the World, to the World."

That said, these past two months, over the course of discussions and deliberations with the managers, we reached the conclusion that it would benefit the Company to be a little more proactive. In light of this, we have now added the word "challenge" to MANI's corporate value.

Support

Japan

050.5212.7790

North America

1.800.674.8375

Tollfree

0120.966.744

Email Support

support@scriptsasia.com

9